{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 4eab065b-4fb3-409e-a8fe-70c5ca090712 --><h2>How should I assess a person intending to travel to a malaria endemic area?</h2><!-- end field 4eab065b-4fb3-409e-a8fe-70c5ca090712 -->","summary":"","htmlStringContent":"<!-- begin item 384b8db4-1aad-48c0-be2b-63ed2d9c58d0 --><!-- begin field 69aaec2b-ccd2-4df6-9948-36bca639d5db --><p><strong>Take a history, asking about:</strong></p><ul><li>The travel itinerary including:<ul><li>Timing — date of travel and duration of trip.</li><li>Countries to be visited including specific regions (rural or urban), transfers and stopovers.</li><li>Reason for travel such as visiting friends and relatives, tourism, backpacking, or work.</li><li>Type of accommodation such as hotel, hostel, local home, or tent.</li><li>Access to appropriate medical care.</li></ul></li><li>Prior travel experience and health beliefs.<ul><li>Some people may mistakenly believe they are immune to malaria.</li></ul></li><li>Past medical history including conditions which may increase risk of severe malaria or affect choice of chemoprophylaxis:<ul><li>Pregnancy or breast feeding.<ul><li>Pregnant women have an increased risk of developing severe or fatal malaria compared to non-pregnant women.</li><li>Certain anti-malarial drugs are contraindicated in pregnancy and breastfeeding.</li></ul></li><li>Immunosuppression (such as HIV infection or dysfunctional/absent spleen):<ul><li>HIV progression may be hastened by acute malaria and the risk of developing severe malaria is increased in HIV infection.</li><li>People with a dysfunctional or absent spleen are at increased risk of severe malaria.</li></ul></li><li>Psychiatric conditions such as depression.<ul><li>A personal or family history of a severe mental health disorder may affect choice of chemoprophylaxis.</li></ul></li><li>Epilepsy and other seizure disorders.<ul><li>Certain anti-malarial drugs are contraindicated in people with seizure disorders.</li></ul></li><li>Inherited haemoglobinopathies such as sickle cell and thalassemia.<ul><li>Malaria causes further haemolysis which significantly increases morbidity and mortality.</li></ul></li><li>Psoriasis.<ul><li>Psoriasis may affect choice of chemoprophylaxis.</li></ul></li><li>Liver or renal impairment.<ul><li>May affect choice and dosage of chemoprophylaxis.</li></ul></li></ul></li><li>Drug and vaccine history, including:<ul><li>All current medications (including those prescribed by secondary care).<ul><li>Many drugs can potentially interact with anti-malarial medication for example antiarrhythmics (such as amiodarone), anticonvulsants, anticoagulants, antiretrovirals, corticosteroids, and bupropion.</li><li>For further information, see the <a data-hyperlink-id=\"e41304f6-fed0-477e-9de1-a98d0025eae1\" href=\"https://bnf.nice.org.uk/\" target=\"_blank\">British National Formulary</a> and the <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/prescribing-information/\">Prescribing</a> section.</li></ul></li><li>Previous malaria chemoprophylaxis taken and any associated problems.</li><li>Immunizations — routine and travel related.</li></ul></li><li>Allergies.</li></ul><p><strong>Assess the risk of malaria using the Public Health England Advisory Committee on Malaria Prevention (ACMP) guidelines.</strong></p><ul><li>The ACMP guidelines are available on the PHE website at <a data-hyperlink-id=\"01300d73-d117-446e-8932-a98d0025eb0b\" href=\"http://www.gov.uk/government/collections/malaria-guidance-data-and-analysis\" target=\"_blank\">www.gov.uk/government/collections/malaria-guidance-data-and-analysis</a>.<ul><li>Check regularly for updates and ensure the latest version is always used as recommendations may change.</li></ul></li><li>The ACMP prophylaxis guidelines are intended for UK-based travellers and may not be appropriate for people resident in endemic areas.<ul><li>For advice on prophylaxis for a person resident in an endemic area, seek expert advice from a travel specialist. Sources of expert advice include:<ul><li>Malaria Reference Laboratory (MRL) — website <a data-hyperlink-id=\"45079173-9c0f-493f-8d16-a98d0025eb45\" href=\"http://www.malaria-reference.co.uk/\" target=\"_blank\">www.malaria-reference.co.uk</a>.</li><li>National Travel Health Network and Centre (NaTHNaC) — advice line for healthcare professionals (0845 602 6712) and website <a data-hyperlink-id=\"541eeb97-1886-479d-bb42-a98d0025eb82\" href=\"http://www.travelhealthpro.org.uk/\" target=\"_blank\">www.travelhealthpro.org.uk</a>.</li><li>TRAVAX (Health Protection Scotland) advice line for healthcare professionals (0141 300 1130) and website <a data-hyperlink-id=\"b95d9286-adff-49a1-aebc-a98d0025ec54\" href=\"http://www.travax.nhs.uk/\" target=\"_blank\">www.travax.nhs.uk</a>.</li></ul></li></ul></li></ul><p><strong>Be aware that malaria prevention is only one aspect of pre-travel advice.</strong></p><ul><li>A comprehensive risk assessment-based package of travel health advice should be provided to the traveller — if the resources or skills are not available for this in primary care, direct the person to a travel specialist.</li><li>Travel risk assessment can be obtained from NaTHNaC and TRAVAX.</li></ul><!-- end field 69aaec2b-ccd2-4df6-9948-36bca639d5db --><!-- end item 384b8db4-1aad-48c0-be2b-63ed2d9c58d0 -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"bc182e54-0542-559e-8534-ea68dfc5108f","slug":"basis-for-recommendation-46c","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field a9cf65d4-a9f8-4ae2-8731-a86400bdbe03 --><h3>Basis for recommendation</h3><!-- end field a9cf65d4-a9f8-4ae2-8731-a86400bdbe03 -->","summary":null,"htmlStringContent":"<!-- begin item 46c7c724-0472-4e1b-9af0-a86400bdbc29 --><!-- begin field 34675ad2-e34f-4adc-939e-a86400bdbe03 --><p>The recommendations on how to assess a person intending to travel to a malaria endemic area are based on the clinical guidelines <em>Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>], <em>Guidelines for malaria prevention in travellers from the UK 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] and <em>CDC Yellow Book 2018. Health information for international travel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>], the fact sheet from the National Travel Health Network and Centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Freedman, 2016</a>].</p><h4>Take a full clinical history</h4><ul><li>Clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>] and [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] recommend a comprehensive pre-travel risk assessment including full clinical history and thorough review of travel itinerary to ensure that safe, effective and appropriate malaria prevention measures can be recommended.</li><li>Several public health guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>] recommend identification of factors that may increase the risk of adverse outcomes in malaria infection. In some cases, avoidance of travel should be recommended. If avoidance of travel is not possible rigorous antimalarial protection is essential.<ul><li>Factors increasing the risk of adverse outcomes in malaria infection include:<ul><li>Pregnancy — pregnant women have an increased risk of developing severe malaria and a higher risk of death compared to non-pregnant women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>Extremes of age — children and the elderly (over 70 years of age) are at particular risk of severe or complicated malaria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>Immunosuppression — people with asplenia or a dysfunctional spleen have an increased risk of severe or fatal malaria. In asplenic individuals, malarial parasitaemia can rise rapidly to very high levels (greater than 50% in <em>P. falciparum </em>infection) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>Complex co-morbidities — increase the risk of severe malaria and may restrict choice of chemoprophylaxis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li></ul></li></ul></li><li>Additional factors that may affect choice or dose of chemoprophylaxis include:<ul><li>Liver impairment — as most antimalarial drugs are excreted or metabolised by the liver, severe liver impairment increases the risk of drug accumulation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>Renal failure — as some chemoprophylactic drugs are excreted by the kidneys, renal impairment may affect drugs choice and dosage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>Psychiatric disorders.<ul><li>Dose related neuropsychiatric adverse effects are well recognized with mefloquine and to a lesser extent with chloroquine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>].</li><li>Public Health England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>]  recommend asking about family history in the risk assessment as risk of epilepsy and major depression is higher in first degree relatives. These conditions in first degree relatives do not contraindicate an antimalarial but may influence choice of drug.</li></ul></li></ul></li></ul><h4>Assess the risk of malaria using the ACMP guidelines</h4><ul><li>Public Health England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] recommend that health professionals use only their Advisory Committee on Malaria Prevention (ACMP) guidelines as the preferred source of guidance for malaria to ensure consistency of advice. </li></ul><!-- end field 34675ad2-e34f-4adc-939e-a86400bdbe03 --><!-- end item 46c7c724-0472-4e1b-9af0-a86400bdbc29 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}